Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.

Schultheis, B; Riebeling, J; Allali, M; Bergmann, U; Kummer, G; Sendler, U; Tannapfel, A; Sendler, A; Strumberg, D

Schultheis, B; Riebeling, J; Allali, M; Bergmann, U; Kummer, G; Sendler, U; Tannapfel, A; Sendler, A; Strumberg, D.

Affiliation

Schultheis B; Department of Hematology and Oncology, University of Bochum, Marienhospital Herne, Herne, Germany.

Int J Clin Pharmacol Ther ; 48(7): 451-2, 2010 Jul.

Article in En | MEDLINE | ID: mdl-20557841

Subject(s)

Adenocarcinoma/drug therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Esophageal Neoplasms/drug therapy; Esophagogastric Junction; Stomach Neoplasms/drug therapy; Adult; Aged; Capecitabine; Cisplatin/administration & dosage; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Docetaxel; Female; Fluorouracil/administration & dosage; Fluorouracil/analogs & derivatives; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids/administration & dosage

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Esophageal Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols / Esophagogastric Junction Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Pharmacol Ther Year: 2010 Document type: Article

Search on Google

XML

PubMed Links